Skip to main content
SpringerLink
Log in

Immunotherapy in the treatment of acute myelogenous leukemia (AML): Rationale, results and future prospects

  • Originalien
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

Patients with AML in complete remission (CR) are immunosuppressed; remission lymphocytes of at least a part of the patients are able to recognize autologous leukemic blasts; the CR represents a minimal residual disease. Thus, important conditions for a potentially successful active immunotherapy are given. Results of most earlier randomized trials on immunotherapy revealed some, but limited benefit with respect to survival. Encouraging effects, however, have been achieved by immunizing CR patients with high-dose neuraminidase-treated allogeneic blasts. Because these data have not been confirmed until now we recently initiated a randomized study utilizing identical treatment protocols. The preliminary results of the ongoing study still do not allow to draw any firm conclusions. Specific monoclonal antibodies or autologous cytotoxic T-cells may be useful tools for future immunotherapy of AML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Al-Rammahy AK, Shipman S, Jackson A, Malcolm A, Levy JG (1980) Evidence for a common leukemia-associated antigen in acute myelogenous leukemia. Cancer Immunol Immunother 9:181–185

    Google Scholar 

  2. Baker MA, Falk JA, Taub RN (1978) Immunotherapy of human acute leukemia: antibody response to leukemia-associated antigens. Blood 52:469–480

    PubMed  Google Scholar 

  3. Baldwin RW, Robins RA (1976) Factors interfering with immunological rejection of tumors. Br Med Bull 32:118–123

    PubMed  Google Scholar 

  4. Bates SE, Suen JY, Tranum BL (1979) Immunological skin testing and interpretation. A plea for uniformity. Cancer 43:2306–2314

    PubMed  Google Scholar 

  5. Bekesi JG, Arneault GSt, Walter L, Holland JF (1972) Immunogenicity of Leukemia L1210 cells after neuraminidase treatment. J Natl Cancer Inst 49:107–118

    PubMed  Google Scholar 

  6. Bekesi JG, Roboz IP, Zimmermann E, Holland JF (1976) Treatment of spontaneous leukemia in AKR mice with chemotherapy, immunotherapy and interferon. Cancer Res 36:631–639

    PubMed  Google Scholar 

  7. Bekesi JG, Holland JF, Fleminger R, Yates J, Henderson ES (1977) Immunotherapeutic efficacy of neuraminidase-treated allogeneic myeloblasts in patients with acute myelocytic leukemia. In: Chirigos MA (ed) Control of Neoplasia by modulation of the Immune System, pp 573–592

  8. Bekesi JG, Holland JF (1979) Impact of specific immunotherapy in acute myelocytic leukemia. In: Neth R, Gallo RC, Hofschneider HP, Mannweiler K (eds) Modern trends in human leukemia III. Springer, Berlin Heidelberg New York, pp 79–87

    Google Scholar 

  9. Blume KG, Beutler E, Bross KJ, Chillar RK, Ellington OB, Fahey JL, Farbstein MJ, Forman StJ, Schmidt GM, Scott EP, Spruce WE, Turner MA, Wolf JL (1980) Bonemarrow ablation and allogeneic marrow transplantation in acute leukemia. N Engl J Med 302:1041–1046

    PubMed  Google Scholar 

  10. Büchner T, Urbanitz D, Hiddemann W, Kamanbroo D, Meister R, Balleisen L, Delvos U, Lagrcze EM, Schmitz-Huebner U, Schulte H, van de Loo J (1979) Intensification of remission induction therapy for acute nonlymphocytic leukemia (ANLL). Blut 39:133–140

    PubMed  Google Scholar 

  11. Büchner T, Urbanitz D, Emmerich B, Fischer JT, Fülle HH, Heinecke A, Hoßfeld DK, Koeppen KM, Labedzki L, Löffler H, Nowrousian MR, Pfreundschuh M, Pralle H, Rühl H, Wendt FC for the AML Cooperative Group (1982) Multicenter Study on Intensified Remission Induction Therapy for Acute Myeloid Leukemia. Leukemia Research, 6:827–831

    PubMed  Google Scholar 

  12. Carcassone Y, Favre R, Sebahoun G, Gartaut JA, Imbert-Xeridot L (1977) Chemo-immunotheray done in maintenance treatment of acute non-lymphoblastic leukemia. In: Mandelli F (ed) Therapy of acute leukemia. Lombardo editore, Roma, pp 715–722

    Google Scholar 

  13. Chan P, Wiernik PH, Lichtenfeld JL (1978) Levamisole, cytosine-arabinoside (ara-c), and daunorubicin (DNR) induction therapy of adult acute non-lymphocytic leukemia (ANLL). Proc Am Assoc Cancer Res Am Soc Clin Oncol 19:370

    Google Scholar 

  14. Cocks P, Powles RL, Chapuis B, Alcxander P (1977). Further evidence of response by leukemia patients in remission to antigen(s) related to acute myelogenous leukemia. Br J Cancer 35:273–279

    PubMed  Google Scholar 

  15. Eppinger-Helft M, Pavlovsky S, Hidalgo G, Sackmann Muriel F, Suarez A, Garay G, Russo C, Santos M, Macchi A, Lein J (1980) Chemoimmunotherapy with corynebacterium parvum in acute myelocytic leukemia. Cancer 45:280–284

    PubMed  Google Scholar 

  16. Ezaki K, Hersh EM, Keating M, Dyre S, Hollinshead A, McCredie KB, Mavligit GM, Gutterman JU (1978) Active specific immunization with allogeneic leukemia associated antigens or irradiated allogeneic leukemia cells in acute leukemia. Cancer 41:70–83

    PubMed  Google Scholar 

  17. Gale RP, Cline MJ (1977) High remission induction rate in acute myeloid leukemia. Lancet I:497–499

    Google Scholar 

  18. Gale RP (1979) Advances in the treatment of acute myelogenous lcukemia. N Engl J Med 300:1189–1192

    PubMed  Google Scholar 

  19. Galton DAG, Kay HEM, Reizenstein P, Penchansky M, Vogler WR, Whittaker JA (1977) Infection and second-remission rates in patients having immunotherapy for acute myeloid leukemia. Lancet I:973

    Google Scholar 

  20. Galton DA, Peto R (1978) Immunotherapy of acute myeloid leukaemia. Br J Cancer 37:1–14

    PubMed  Google Scholar 

  21. Granatek CH, Ezaki K, Hersh EM, Keating MJ, Rasmussen S (1981) Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapy. Cancer 47:272–279

    PubMed  Google Scholar 

  22. Gutterman JU, Rodriguez V, Mavligit G, Burgess MA, Gehan E, Hersh EM, McCredie KB, Reed R, Smith T, Bodey GP, Freireich EJ (1974) Chemoimmunotherapy of adult acute leukemia prolongation of remission in myeloblastic leukaemia with B.C.G. Lancet II:1406–1409

    Google Scholar 

  23. Harris R, Zuhrie SR, Freeman CB, Tayler GM, MacIvery JE, Geary CG, Delamore IW, Hull PJ, Tooth JA (1978) Active Immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions. Br J Cancer 37:282–288

    PubMed  Google Scholar 

  24. Haubeck HD, Kölsch E (1983) Induction of specific T suppressor cells to the BALB/C plasmocytoma ADJ-PC-5 during carly stages of tumorigenesis. Immunology (in press)

  25. Kano K, Nishimake T, Palosuo T, Loza K, Milgrom F (1978) Detection of circulating immune-complexes by the inhibition of antibody. Clin Immunol Immunopathol 9:425–435

    PubMed  Google Scholar 

  26. Kuntz MM, Innes JB, Weksler ME (1976) Lymphocyte transformation induced by autologous cells. J Exp Med 143:1042–1046

    PubMed  Google Scholar 

  27. Lindemalm ChS, Killander A, Björkholm M, Brenning G, Engstedt L, Franzen L, Gahrton G, Gullbring B, Holm G, Höglund S, Hörnsten P, Jameson S, Killander D, Klein E, Lantz B, Lockner D, Lönnqvist B, Mellstedt H, Palmbad J, Pauli C, Reizenstein P, Simonsson B, Skarberg KO, Uden AM, Vanky F, Wadman B (1978) Adjuvant Immunotherapy in acute nonlymphocytic leukemia. Cancer Immunol Immunother 4:179–183

    Google Scholar 

  28. Mandelli F, Amadori S, Dini E, Grignani F, Leonis P, Liso V, Martelli M, Neri A, Petti MC, Ferrini PR (1981) Randomized clinical trial of immunotherapy and androgenotherapy for remission maintenance in acute non-lymphocytic leukemia. Leukemia Res 5:447–452

    Google Scholar 

  29. Mathé G, Pouillart P, Lapeyraque F (1969) Active immunotherapy of L 1210 leukemia applied after the graft of tumor cells. Br J Cancer 23:814–824

    PubMed  Google Scholar 

  30. McCredie KB, Bodey GP, Freireich EJ, Hester JP, Rodriguez V, Keating MJ (1981) Chemoimmunotherapy of adult acute leukemia. Cancer 47:1256–1261

    PubMed  Google Scholar 

  31. Miller RA, Maloney DG, Warnke R, Levy R (1982) Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517–522

    PubMed  Google Scholar 

  32. MRC Report (1978) Immunotherapy of acute myeloid leukaemia. Br J Cancer 37:1–14

    Google Scholar 

  33. Murphy S, Hersh E (1978) Immunotherapy of leukemia and lymphoma. Semin Hematol 15:181–203

    PubMed  Google Scholar 

  34. Omura GA, Vogler WR, Lefante J, Silberman H, Knospe W, Gordon D, Jarrell R (1982) Treatment of acute myelogenous leukemia: Influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy. Cancer 49:1530–1536

    PubMed  Google Scholar 

  35. Pauli C, Vanky F, Hast R, Lindemalm C, Uden AM, Reizenstein P (1978) Cell-mediated immunity in human acute myeloblastic leukemia. Cancer Immunol Immunother 5:1–10

    Google Scholar 

  36. Peterson BA, Bloomfield CD, Bosl GJ, Gibbs G, Malloy M (1980) Intensive five-drug combination chemotherapy for adult acute non-lymphocytic leukemia. Cancer 46:663–668

    PubMed  Google Scholar 

  37. Pincus JH, Jameson AK, Brandt AE (1981) Immunotherapy of L1210 Leukemia using neuraminidase-modified plasma membranes combined with chemotherapy. Cancer Res 41:3082–3086

    PubMed  Google Scholar 

  38. Powles RL, Russel J, Lister TA, Oliver T, Whitehouse JMA, Malpas J, Chapuis B, Crowther D, Alexander P (1977) Immunotherapy for acute myelogenous leukemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br J Cancer 35:265–272

    PubMed  Google Scholar 

  39. Preissler HD, Rustum Y, Henderson ES, Bjornsson S, Creaven PJ, Higby DJ, Freeman A, Gailani S, Naeher C (1979) Treatment of acute nonlymphocytic leukemia: Use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood 53:454–464

    Google Scholar 

  40. Rees JKH, Hayhoe FGL (1981) The treatment of acute myeloid leukemia (AML) — Some factors affecting the success rate. VI. Meeting Intern Soc Haematol Eur Afric Div Abstr 232

  41. Rees JKH, Sandler RM, Cahllener J, Hayhoe FGJ (1977) Treatment of acute myeloid leukacmia with a triple cytotoxic regime: DAT. Br J Cancer 36:770–776

    PubMed  Google Scholar 

  42. Rühl H, Fülle HH, Koeppen KM, Schwerdtfeger R (1981) Adjuvant specific immunotherapy in maintenance treatment of adult acute non-lymphocytic leukemia. Klin Wochenschr 59:1189–1193

    PubMed  Google Scholar 

  43. Schuepbach J, Sauter C (1981) Inverse correlation of antiviral antibody titers and the remission length in patients treated with viral oncolysate: A possible new prognostic sign in acute myelogenous leukemia. Cancer 48:1363–1367

    PubMed  Google Scholar 

  44. Skipper HE, Schabel FM, Trader MW, Laster WR (1969) Response to therapy of spontaneous, first passage, and long passage lines of ak leukemia. Cancer Chemother Rep 53:345–366

    PubMed  Google Scholar 

  45. Sulitzeanu D, Weiss DW (1981) Antigen and Immunogen — A question of terminology. Cancer Immunol Immunother 11:291–292

    Google Scholar 

  46. Thomas ED, Buckner CD, Clift RA, Fefer A, Johnson FL, Neiman PE, Sale GE, Sanders JE, Singer JW, Shulman H, Storb R, Weiden PL (1979) Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 301:597–599

    PubMed  Google Scholar 

  47. Uden AM, Lindemalm C, Pauli C, Vanky F, Reizenstein P (1978) Effects of immunotherapy and chemotherapy on immunocompetence. A study of patients with acute myeloblastic leukemia in remission. Cancer Immunol Immunother 4:239–245

    Google Scholar 

  48. Urbanitz D, Büchner Th, Kamanabroo D, Hiddemann W, Schulte H, van de Loo J (1981) Intensified remission induction therapy for acute nonlymphocytic leukemia (ANLL) Treatment report on 60 patients. Blut 43:129–133

    PubMed  Google Scholar 

  49. Vogler WR, Chan YK (1974) Prolonging remission in myeloblastic leukaemia by tice-strain bacillus Calmette-Guerin. Lancet I:128–131

    Google Scholar 

  50. Vogler WR, Gordon DS, Smalley RV, Heffner ThJ, Trulock P, Guzman G, Barbieri B, Hearn E (1981a) Serial immunologic assessment during a randomized trial of chemoimmunotherapy in acute myelogenous leukemia. Cancer Immunol Immunother 11:97–107

    Google Scholar 

  51. Vogler WR (1981b) Results of randomized trials of immunotherapy for acute leukemia. Cancer Immunol Immunother 9:15–21

    Google Scholar 

  52. Vuvan H, Fiere D, Doillon M, Martin C, Coiffier B, Felman P, Bryon PA, Favre-Gilly J, Revol L (1978) BCG therapy in acute non lymphoid leukaemias. Scand J Haematol 21:40–46

    PubMed  Google Scholar 

  53. Weinstein HJ, Mayer RJ, Rosenthal DS, Camitta BM, Coral FS, Nathan DG, Frei III E (1980) Treatment of acute myelogenous leukemia in children and adults. N Engl J Med 303:473–478

    PubMed  Google Scholar 

  54. Whiteside MG, Cauchi MN, Paton Ch, Stone J (1976) Chemoimmunotherapy for maintenance in acute myeloblastic leukemia. Cancer 38:1581–1586

    PubMed  Google Scholar 

  55. Whittaker JA, Bailey-Wood R, Hutchins S (1980) Active immunotherapy for the treatment of acute myelogenous leukaemia: report of two controlled trials. Br J Haematol 45:389–400

    PubMed  Google Scholar 

  56. Whittaker JA, Reizenstein P, Callender ST, Cornwell GG, Delamore IW, Gale RP, Gobbi M, Jacobs P, Lantz B, Maiolo AT, Rees JKH, van Slyck EJ, Vu Van H (1981) Long survival in acute myelogenous leukaemia: an international collaborative study. Br Med J 282:692–695

    Google Scholar 

  57. Wiernik PH, Holland JF, Rai J, Cuttner J, Ellison RR, Glidewell O, Wesley M (1981) Comparison of bone marrow transplantation (BMT) with chemotherapy alone (CT) for remission maintenance in acute myelogenous leukemia (AML). ASCO (Abstr) 484

  58. Zarling JM, Bach FA (1979) Continous culture of T-cells cytotoxic for autologous leukemia cells. Nature 280:685–689

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Med. Univ.-Klinik, Domagkstr. 3, D-4400, Münster, Germany

    D. Urbanitz, Th. Büchner, H. Pielken & J. van de Loo

Authors
  1. D. Urbanitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Th. Büchner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Pielken
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. van de Loo
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Dedicated to Professor Dr. R. Gross on the occasion of his birthday on October 1, 1983

Rights and permissions

Reprints and permissions

About this article

Cite this article

Urbanitz, D., Büchner, T., Pielken, H. et al. Immunotherapy in the treatment of acute myelogenous leukemia (AML): Rationale, results and future prospects. Klin Wochenschr 61, 947–954 (1983). https://doi.org/10.1007/BF01550267

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01550267

Key words

Search

Navigation